Ad
Saturday, 1 October 2016
Morphosys moves closer to getting first antibody drug on market
FRANKFURT (Reuters) - German biotech Morphosys moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment